Tirzepatide clinical trials
Every study registered on ClinicalTrials.gov that lists Tirzepatide as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.
- Registered studies
- 300
- Active or recruiting
- 199
- Completed
- 91
- With posted results
- 47
- Planned or actual enrollment
- 24,783,632participants, summed
| Phase | Studies | Breakdown |
|---|---|---|
| Early phase 1 | 6 | 0 completed, 6 active or recruiting, 0 stopped, 0 other |
| Phase 1 | 34 | 24 completed, 10 active or recruiting, 0 stopped, 0 other |
| Phase 2 | 73 | 16 completed, 53 active or recruiting, 2 stopped, 2 other |
| Phase 3 | 57 | 31 completed, 26 active or recruiting, 0 stopped, 0 other |
| Phase 4 | 48 | 5 completed, 41 active or recruiting, 2 stopped, 0 other |
| Not applicable | 29 | 0 completed, 27 active or recruiting, 0 stopped, 2 other |
| Observational | 53 | 15 completed, 36 active or recruiting, 2 stopped, 0 other |
Conditions studied
- Obesity109
- Overweight35
- Type 2 Diabetes26
- Obesity & Overweight25
- Diabetes Mellitus, Type 218
- Type 2 Diabetes Mellitus10
- Healthy9
- Obesity (Disorder)8
- Obesity and Overweight7
- Weight Loss6
- Obesity and Obesity-related Medical Conditions6
- Tirzepatide5
Lead sponsors
- Eli Lilly and Company80
- Brigham and Women's Hospital11
- Novo Nordisk A/S6
- The Cleveland Clinic6
- University of Colorado, Denver4
- University of Texas Southwestern Medical Center4
- Mayo Clinic3
- Dasman Diabetes Institute3
The registry, study by study
Showing the 160 most relevant of 300 studies (active first, then newest start date). Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.
| Study | Phase | Status | Start | n | Sponsor |
|---|---|---|---|---|---|
| NCT07265752Tirzepatide for the Treatment of Cannabis Use Disorder | Phase 2 | Not yet recruiting | Mar 2027 | 6 | Brigham and Women's Hospital |
| NCT07847515Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients | Observational | Not yet recruiting | Feb 2027 | 80 | Nanjing First Hospital, Nanjing Medical University |
| NCT07787936GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Observational | Not yet recruiting | Jan 2027 | 150 | Miedziowe Centrum Zdrowia SA |
| NCT07622992Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery | Observational | Not yet recruiting | Jan 2027 | 96 | Mario Musella MD |
| NCT07078838Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | Jan 2027 | 40 | UNC Lineberger Comprehensive Cancer Center |
| NCT07829198Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Phase 3 | Not yet recruiting | Jan 2027 | 70 | Universidade do Porto |
| NCT07874828PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study | Phase 2 | Not yet recruiting | Dec 2026 | 30 | M.D. Anderson Cancer Center |
| NCT06180616Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Phase 2 | Not yet recruiting | Dec 2026 | 40 | Royal North Shore Hospital |
| NCT07468552Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Phase 2 | Not yet recruiting | Nov 2026 | 100 | National Institute on Drug Abuse (NIDA) |
| NCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | Not yet recruiting | Nov 2026 | 350 | Boehringer Ingelheim |
| NCT07796477A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | Phase 2 | Not yet recruiting | Nov 2026 | 240 | CSPC Ouyi Pharmaceutical Co., Ltd. |
| NCT07349641A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | Nov 2026 | 55 | National Cancer Institute (NCI) |
| NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Phase 4 | Not yet recruiting | Nov 2026 | 60 | Jing Luo |
| NCT07027969Metabolic Surgery for Atrial Fibrillation Elimination | Phase 4 | Not yet recruiting | Nov 2026 | 100 | Ali Aminian |
| NCT07878494Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia | N/A | Not yet recruiting | Nov 2026 | 30 | Stanford University |
| NCT07812636Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer | Early Ph 1 | Not yet recruiting | Nov 2026 | 15 | Milton S. Hershey Medical Center |
| NCT07609160Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals | N/A | Not yet recruiting | Nov 2026 | 108 | Acibadem University |
| NCT07099742Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) | Observational | Not yet recruiting | Nov 2026 | 364 | Dr. Md. Alimur Reza |
| NCT07868354A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication | Phase 1 | Recruiting | Oct 2026 | 60 | Novo Nordisk A/S |
| NCT07825857Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Oct 2026 | 228 | University of Texas Southwestern Medical Center |
| NCT07809568Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes | Observational | Not yet recruiting | Oct 2026 | 330 | Universiti Sains Malaysia |
| NCT07846865Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial | Phase 2/Phase 3 | Not yet recruiting | Oct 2026 | 256 | Woolcock Institute of Medical Research |
| NCT07758231Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics | Phase 1 | Not yet recruiting | Oct 2026 | 5 | University of Wisconsin, Madison |
| NCT07387796Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | N/A | Recruiting | Oct 2026 | 40 | The University of Texas at Dallas |
| NCT07782359Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib | Phase 1 | Not yet recruiting | Oct 2026 | 30 | University of Chicago |
| NCT07845500A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Phase 3 | Recruiting | Sep 2026 | 660 | Pfizer |
| NCT07817875Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Phase 3 | Recruiting | Sep 2026 | 150 | Eli Lilly and Company |
| NCT07846956NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | Observational | Not yet recruiting | Sep 2026 | 28 | Istanbul Saglik Bilimleri University |
| NCT07734792Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial | Phase 2/Phase 3 | Not yet recruiting | Sep 2026 | 726 | yifang zhu |
| NCT07734870Tirzepatide for Treatment of CCCA | Phase 2 | Recruiting | Sep 2026 | 20 | Johns Hopkins University |
| NCT07803744A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | Phase 1 | Recruiting | Sep 2026 | 18 | Eli Lilly and Company |
| NCT07777575Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Phase 4 | Recruiting | Sep 2026 | 150 | Technical University of Munich |
| NCT07728812Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | N/A | Not yet recruiting | Sep 2026 | 424 | Phenomix Sciences |
| NCT07715929Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients | Phase 4 | Not yet recruiting | Sep 2026 | 710 | Yunlong Wang |
| NCT07811895Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer | N/A | Not yet recruiting | Sep 2026 | 1,510 | RenJi Hospital |
| NCT07756359Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) | Phase 4 | Not yet recruiting | Sep 2026 | 20 | University of North Carolina, Chapel Hill |
| NCT07747805GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD | Phase 2 | Not yet recruiting | Aug 2026 | 30 | The Cleveland Clinic |
| NCT07842640A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight | Phase 1 | Recruiting | Aug 2026 | 84 | Ascletis Pharma (China) Co., Limited |
| NCT07191873Tirzepatide in Idiopathic Intracranial Hypertension Trial | Phase 4 | Recruiting | Aug 2026 | 60 | Duke University |
| NCT07693608An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Phase 2 | Enrolling by invitation | Aug 2026 | 45 | University of Texas Southwestern Medical Center |
| NCT07720466Salivary Function and Dental Changes During GLP-1 Therapy | Observational | Not yet recruiting | Aug 2026 | 40 | Bilecik Seyh Edebali Universitesi |
| NCT06732245Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Phase 2 | Not yet recruiting | Aug 2026 | 224 | Biomed Industries, Inc. |
| NCT07728318Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients | N/A | Not yet recruiting | Aug 2026 | 52 | Akhtar Saeed Medical and Dental College |
| NCT07760532Comparing Facial Aging Between Identical Twins With 3D Imaging | Observational | Not yet recruiting | Aug 2026 | 200 | Ponsky Facial Aesthetics And Plastic Surgery, Llc |
| NCT07554638Incretin Therapies in Obesity-related HFpEF | Phase 4 | Recruiting | Aug 2026 | 50 | Columbia University |
| NCT07213323Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | N/A | Recruiting | Aug 2026 | 50 | Hospices Civils de Lyon |
| NCT07619989Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | N/A | Recruiting | Aug 2026 | 24 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| NCT07630454Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Phase 4 | Not yet recruiting | Aug 2026 | 602 | Yunlong Wang |
| NCT07676331Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Phase 2 | Not yet recruiting | Aug 2026 | 168 | Universitaire Ziekenhuizen KU Leuven |
| NCT07671248Tirzepatide in the Treatment of Cannabis Use Disorder | Phase 3 | Not yet recruiting | Aug 2026 | 15 | McMaster University |
| NCT07671391A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants | Phase 2 | Not yet recruiting | Aug 2026 | 60 | Shanghai Zhongshan Hospital |
| NCT07298915The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Phase 3 | Not yet recruiting | Aug 2026 | 24 | University of Virginia |
| NCT07668765GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | Observational | Not yet recruiting | Aug 2026 | 100 | Gazi University |
| NCT07573163Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Phase 2 | Recruiting | Jul 2026 | 34 | Alaa Sada |
| NCT07588438Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Phase 4 | Recruiting | Jul 2026 | 160 | Las Rías Medical Center |
| NCT07697391AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | Phase 4 | Not yet recruiting | Jul 2026 | 285 | The First Affiliated Hospital of Anhui Medical University |
| NCT07738276Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | Phase 3 | Not yet recruiting | Jul 2026 | 60 | Shahid Beheshti University of Medical Sciences |
| NCT07835360Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes | Observational | Recruiting | Jul 2026 | 200 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT06820281Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Phase 2 | Recruiting | Jul 2026 | 44 | Victor Chang Cardiac Research Institute |
| NCT07635953New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Phase 3 | Not yet recruiting | Jul 2026 | 296 | Sun Yat-sen University |
| NCT07720414Effects of GLP-1 RAs on Human Lactation Outcomes | Observational | Recruiting | Jul 2026 | 18 | University of Colorado, Denver |
| NCT07700030High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE) | N/A | Not yet recruiting | Jul 2026 | 32 | NYU Langone Health |
| NCT07706088Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy | Phase 4 | Not yet recruiting | Jul 2026 | 40 | Post Graduate Institute of Medical Education and Research, Chandigarh |
| NCT07866183Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study | N/A | Recruiting | Jun 2026 | 120 | National Medical Research Center for Therapy and Preventive Medicine |
| NCT07707778Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | Phase 4 | Enrolling by invitation | Jun 2026 | 60 | National Taiwan University Clinical Trial Center |
| NCT07382024Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation | N/A | Not yet recruiting | Jun 2026 | 200 | National Taiwan University Hospital |
| NCT07702461Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Observational | Recruiting | Jun 2026 | 300 | Ohio State University |
| NCT07046819Tirzepatide in MetALD | Phase 2 | Recruiting | Jun 2026 | 120 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT07257484Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Phase 4 | Recruiting | Jun 2026 | 30 | Weill Medical College of Cornell University |
| NCT07602699Multi-Site Trial of Tirzepatide for Smoking Cessation | Phase 2 | Recruiting | Jun 2026 | 300 | University of Southern California |
| NCT07444073Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | Observational | Not yet recruiting | Jun 2026 | 440 | National University of Singapore |
| NCT07605247Tirzepatide in the Treatment of Endometrial Cancer | Phase 2 | Not yet recruiting | Jun 2026 | 30 | Rutgers, The State University of New Jersey |
| NCT07858864GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | Observational | Recruiting | May 2026 | 42 | Istanbul Saglik Bilimleri University |
| NCT07650149Genetic, Microbiological and Behavioral Factors in Obesity | Observational | Recruiting | May 2026 | 200 | Jan Kochanowski University |
| NCT07527910A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Phase 2 | Recruiting | May 2026 | 204 | Regeneron Pharmaceuticals |
| NCT07559500Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Phase 1 | Recruiting | May 2026 | 176 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT07284511A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar | Phase 2/Phase 3 | Recruiting | May 2026 | 105 | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| NCT07574723Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity | N/A | Recruiting | May 2026 | 68 | Dasman Diabetes Institute |
| NCT07633639GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | N/A | Recruiting | May 2026 | 200 | China-Japan Friendship Hospital |
| NCT07179120Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Phase 2 | Not yet recruiting | May 2026 | 180 | First Affiliated Hospital of Wenzhou Medical University |
| NCT07567378CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | Observational | Not yet recruiting | May 2026 | 30 | JULIO GRANADOS MONTIEL |
| NCT07588984GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | Observational | Not yet recruiting | Apr 2026 | 2,310 | Noom Inc. |
| NCT07555730AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Phase 4 | Not yet recruiting | Apr 2026 | 400 | Huazhong University of Science and Technology |
| NCT07065552Tirzepatide in Obesity-Driven Endometrial Cancer | Early Ph 1 | Recruiting | Apr 2026 | 20 | UNC Lineberger Comprehensive Cancer Center |
| NCT07228741Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Phase 2 | Recruiting | Apr 2026 | 20 | St. Jude Children's Research Hospital |
| NCT07653412Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | Observational | Recruiting | Apr 2026 | 220 | National and Kapodistrian University of Athens |
| NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Phase 4 | Recruiting | Apr 2026 | 40 | Mayo Clinic |
| NCT07107334A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | Phase 2 | Recruiting | Apr 2026 | 20 | University of Florida |
| NCT06811324Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults | Phase 2 | Recruiting | Apr 2026 | 20 | The University of Texas Health Science Center at San Antonio |
| NCT07504172Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity | Observational | Not yet recruiting | Apr 2026 | 1,700 | Radboud University Medical Center |
| NCT07457437Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment | N/A | Recruiting | Apr 2026 | 60 | University of Exeter |
| NCT07521631Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Phase 2 | Recruiting | Mar 2026 | 372 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| NCT07589322Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | N/A | Recruiting | Mar 2026 | 120 | Tri-Service General Hospital (TSGH) |
| NCT07443956Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | N/A | Recruiting | Mar 2026 | 45 | NHS Greater Glasgow and Clyde |
| NCT07463846A Study to Evaluate ALN-2232 in Participants With Obesity | Phase 1/Phase 2 | Recruiting | Mar 2026 | 156 | Alnylam Pharmaceuticals |
| NCT07492563Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay | Observational | Not yet recruiting | Mar 2026 | 300 | LABORATORIOS INDUFAR |
| NCT07483801DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Phase 4 | Not yet recruiting | Mar 2026 | 112 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07220473Tirzepatide to Slow Biological Aging | Phase 2 | Recruiting | Feb 2026 | 90 | The University of Texas Medical Branch, Galveston |
| NCT07685834Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss | N/A | Active, not recruiting | Feb 2026 | 30 | Sofwave Medical LTD |
| NCT07438444A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Phase 4 | Active, not recruiting | Feb 2026 | 344 | Eli Lilly and Company |
| NCT07095517Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | Phase 1 | Recruiting | Feb 2026 | 20 | Massachusetts General Hospital |
| NCT07481747Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Phase 3 | Recruiting | Feb 2026 | 2,539 | Hudson Biotech |
| NCT07176663Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | N/A | Not yet recruiting | Feb 2026 | 15 | Shahid Beheshti University of Medical Sciences |
| NCT06651177Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Phase 2 | Recruiting | Jan 2026 | 310 | T. John Winhusen, PhD |
| NCT07382388A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis | Observational | Not yet recruiting | Jan 2026 | 70 | Peking University Third Hospital |
| NCT07398222Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study | Observational | Recruiting | Jan 2026 | 30 | Hospital Israelita Albert Einstein |
| NCT07354880Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease | Phase 4 | Not yet recruiting | Jan 2026 | 30 | University Medical Centre Ljubljana |
| NCT07292519Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Phase 2 | Not yet recruiting | Jan 2026 | 46 | South West Sydney Local Health District |
| NCT07299084A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Phase 1 | Active, not recruiting | Jan 2026 | 40 | Eli Lilly and Company |
| NCT07640139Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Observational | Enrolling by invitation | Jan 2026 | 125,000 | Indiana University |
| NCT07423247Tirzepatide (Spartina) in Obese Kidney Transplant Recipients | Phase 4 | Recruiting | Jan 2026 | 30 | Shahid Beheshti University of Medical Sciences |
| NCT07364175A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | N/A | Recruiting | Jan 2026 | 60 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07373834Tirzepatide and Muscle Outcomes in Obesity | N/A | Recruiting | Jan 2026 | 30 | University Medical Centre Ljubljana |
| NCT07319975Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | N/A | Not yet recruiting | Dec 2025 | 48 | Istanbul Galata University |
| NCT07058155Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | Phase 4 | Recruiting | Dec 2025 | 70 | The Cleveland Clinic |
| NCT07326111A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Phase 4 | Recruiting | Dec 2025 | 198 | University of Bonn |
| NCT07229170Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients | Observational | Recruiting | Dec 2025 | 150 | San Raffaele Telematic University |
| NCT07247084A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Phase 4 | Recruiting | Nov 2025 | 3,000 | Eli Lilly and Company |
| NCT05933499Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Phase 2 | Recruiting | Nov 2025 | 63 | Massachusetts General Hospital |
| NCT07202247Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Phase 2 | Recruiting | Nov 2025 | 60 | City of Hope Medical Center |
| NCT07245771Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity | Phase 1/Phase 2 | Recruiting | Nov 2025 | 104 | Ikaria Bioscience Pty Ltd |
| NCT07128082The Long COVID Treatment Trial | Phase 2 | Active, not recruiting | Oct 2025 | 1,000 | Scripps Translational Science Institute |
| NCT07165028A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Recruiting | Oct 2025 | 4,500 | Eli Lilly and Company |
| NCT07154719GLP-1R Actions on Muscle and the Skeleton | Phase 4 | Recruiting | Oct 2025 | 50 | Pennington Biomedical Research Center |
| NCT06994338Tirzepatide for Alcohol Use Disorder | Phase 2 | Recruiting | Oct 2025 | 42 | University of Southern California |
| NCT07156331Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes | Observational | Not yet recruiting | Oct 2025 | 20 | Kristin Clemens |
| NCT06801015Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Phase 4 | Active, not recruiting | Oct 2025 | 30 | Mayo Clinic |
| NCT06847399Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Phase 2 | Recruiting | Sep 2025 | 105 | Johns Hopkins University |
| NCT06727331Study of Tirzepatide for Recovery and Alcohol Use Management | Phase 2 | Recruiting | Sep 2025 | 20 | Brigham and Women's Hospital |
| NCT07188545Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Observational | Active, not recruiting | Sep 2025 | 23,280,000 | Ohio State University |
| NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Phase 2 | Recruiting | Sep 2025 | 32 | University of Michigan |
| NCT07115069Comparison of Body Composition Changes With Weight Loss Interventions | Observational | Active, not recruiting | Aug 2025 | 60 | Vanderbilt University Medical Center |
| NCT06885736LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | N/A | Recruiting | Aug 2025 | 232 | Dasman Diabetes Institute |
| NCT07096908Tirzepatide Use in People With Obesity and Type 1 Diabetes | Phase 4 | Recruiting | Jul 2025 | 60 | Dasman Diabetes Institute |
| NCT06861439GLP-1s to Enhance Lasting Optimal Weight | Phase 4 | Active, not recruiting | Jul 2025 | 40 | Wake Forest University Health Sciences |
| NCT06759701Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Early Ph 1 | Recruiting | Jul 2025 | 30 | M.D. Anderson Cancer Center |
| NCT07042672Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | Observational | Recruiting | Jul 2025 | 80 | Haukeland University Hospital |
| NCT0704198324-h Energy Expenditure and Anti-obesity Medication | Observational | Enrolling by invitation | Jul 2025 | 30 | University of Pisa |
| NCT06934642Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Early Ph 1 | Recruiting | Jun 2025 | 8 | University of New Mexico |
| NCT06937086Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Phase 3 | Recruiting | Jun 2025 | 350 | Eli Lilly and Company |
| NCT06937099Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Phase 3 | Recruiting | Jun 2025 | 290 | Eli Lilly and Company |
| NCT07000955Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Phase 1/Phase 2 | Active, not recruiting | Jun 2025 | 98 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07293325Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | N/A | Recruiting | Jun 2025 | 66 | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| NCT07094568Tirzepatide vs Liraglutide in Bone | Observational | Recruiting | May 2025 | 72 | National and Kapodistrian University of Athens |
| NCT06976853Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Phase 2 | Recruiting | May 2025 | 60 | Washington University School of Medicine |
| NCT06962280A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active, not recruiting | May 2025 | 465 | Eli Lilly and Company |
| NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Phase 1/Phase 2 | Recruiting | May 2025 | 150 | Arrowhead Pharmaceuticals |
| NCT06965413A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Phase 2 | Active, not recruiting | May 2025 | 285 | Hoffmann-La Roche |
| NCT06939088Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Phase 2 | Recruiting | May 2025 | 108 | Anders Fink-Jensen, MD, DMSci |
| NCT06901245Tirzepatide in PWS, HO and GNSO | Phase 4 | Recruiting | May 2025 | 36 | Grace Kim |
| NCT07057310Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Phase 4 | Enrolling by invitation | May 2025 | 30 | Mayo Clinic |
| NCT06914895A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active, not recruiting | Apr 2025 | 905 | Eli Lilly and Company |
| NCT06802081TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Phase 2 | Recruiting | Apr 2025 | 100 | The Cleveland Clinic |
| NCT06897475A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Recruiting | Mar 2025 | 200 | Eli Lilly and Company |
| NCT067215072024 Tirzepatide-Bariatric Surgery | Phase 4 | Recruiting | Mar 2025 | 50 | Marlene Starr |
| NCT06857942A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Phase 4 | Recruiting | Mar 2025 | 200 | Eli Lilly and Company |
| NCT06734273Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Early Ph 1 | Active, not recruiting | Mar 2025 | 42 | Nicholas Skertich |
| NCT06864026A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Active, not recruiting | Mar 2025 | 200 | Eli Lilly and Company |
| NCT06582875Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Phase 2 | Recruiting | Mar 2025 | 126 | University of Colorado, Denver |
| NCT06774079Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Phase 4 | Recruiting | Mar 2025 | 24 | University of Miami |
Run this search on ClinicalTrials.gov → Query term: tirzepatide OR LY3298176